Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Reclipsen Tabs 6X28 By Actavis Pharma

Image 0 of Reclipsen Tabs 6X28 By Actavis PharmaImage 1 of Reclipsen Tabs 6X28 By Actavis Pharma

Reclipsen Tabs 6X28 By Actavis Pharma

Call for Price

Reclipsen Tabs 6X28 By Actavis Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3680220/RXB10034703/RXA319799
Size : 6X28
Selling UoM : EA
NDC: 52544-0954-28
UPC Barcode : 352544954289
Supplier: 0050000679 ACTAVIS PHARMA INC/GENERIC
Supplier Material : 095428
Generic Code : 017616 DESOGESTREL-ETHINYL ESTRADIOL ORAL TABLE
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type :

Have a question?

  Call for Price

Product Description.:

WATSON, 954 or P
tablet , multi-colored , round round
21 white (954) 7 green (P)Debossed

Reclipsen may cause weight gain or loss.

This drug may also cause the following symptoms that are related to weight gain or loss:

* Obesity Obesity
* Weight gain Weight gain


Medical Source Information
Yellow highlights indicate symptoms related to weight gain or loss.

Use of desogestrel-ethinyl estradiol is contraindicated for women who are known or suspected of having the following conditions: thrombophlebitis or thromboembolic disorders, a past history of deep vein thrombophlebitis or thromboembolic disorders, cerebral vascular or coronary artery disease (current or history), valvular heart disease with thrombogenic complications, severe hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilization, known or suspected carcinoma of the breast (or personal history of breast cancer), carcinoma of the endometrium or other known or suspected estrogen dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use, hepatic tumors (benign or malignant) or active liver disease, known or suspected pregnancy, or heavy smoking (15 or more cigarettes per day) and over age 35.

Oral contraceptives also increase the risk for stroke in women with other underlying risk factors such as certain inherited or acquired thrombophilias, hyperlipidemias, and obesity. Women with migraine (particularly migraine with aura) who take combination oral contraceptives may be at an increased risk of stroke.

Gastrointestinal side effects have included nausea,vomiting, abdominal pain, cramps, bloating, cholestatic jaundice and change in weight or appetite. Some reports suggested an association between oral contraceptive use and gallbladder disease.

Many of the adverse effects experienced by women on oral contraceptive combination products are related to a relative excess or deficiency of the estrogen and progestin components of these formulations. The following categorizes many of the frequent adverse effects by relative excess or deficiency of these components. Progestin Excess: acne, oily skin breast tenderness depression tiredness, fatigue hair loss hypertension increased appetite weight gain cholestatic jaundice. Progestin Deficiency: late breakthrough bleeding amenorrhea hypermenorrhea. Estrogen Excess: nausea headache melasma hypertension breast tenderness edema. Estrogen Deficiency: early/mid-cycle breakthrough bleeding increased spotting hypomenorrhea.

Side Effects to Watch
Watch closely for the following side effects and notify your physician immediately should any of these develop:

* Abnormal bruising or signs of bleeding such as bleeding from the gums, nose, digestive tract, vagina (females), faintness, dizziness, loss of consciousness, or rash (signs of problems with blood clot formation)

Lab and Diagnostic Tests
If certain symptoms develop, ask your physician whether you need the following lab tests or other diagnostic tests (if you've not already had them):

* Blood tests to assess normal clotting - in people who develop signs of bleeding such as abnormal bruising or signs of bleeding including bleeding from the gums, nose, digestive tract, vagina (females), faintness, dizziness, loss of consciousness, or rash
* Monitor estradiol and glucose